Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?COVID-19 시대의 전신 면역 억제: 우리의 기준을 재고해야 합니까?Review Published on 2020-08-012022-09-11 Journal: Journal der Deutschen Dermatologischen Gesellschaf [Category] 치료제, [키워드] antiviral immunity Autoimmune disease Autoimmune diseases Cardiopulmonary Care Chloroquine Course COVID-19 disease doxycycline doxycycline) Effect effective therapy higher risk Hydroxychloroquine immunoglobulins immunomodulating Immunosuppression immunosuppressive immunosuppressive therapy indication inhibitors intrinsic metabolic conditions Older pandemic Patient pause principle reduction rituximab SARS-CoV-2 SARS-CoV-2 pandemic suppress systemic the SARS-CoV-2 therapy vaccination [DOI] 10.1111/ddg.14194 PMC 바로가기 [Article Type] Review
When the COVID-19 pandemic changed the follow-up landscape of chronic kidney disease: a survey of real-world nephrology practiceResearch Article Published on 2020-07-282022-10-28 Journal: Renal failure [Category] COVID-19, [키워드] Analysis analyzed biopsies Care changed China Chronic kidney disease CKD collected Comorbidities conditions coronavirus disease COVID-19 COVID-19 pandemic demographic data diagnoses dialysis Follow-up immunosuppressive Immunosuppressive treatment initiated kidney Laboratory management Medicine pandemic Participants Patient patients proportion reached Result risk factor risk of COVID-19 significantly higher Telemedicine [DOI] 10.1080/0886022X.2020.1798783 PMC 바로가기 [Article Type] Research Article
The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus InfectionsReview Published on 2020-07-282022-10-28 Journal: Biology [Category] COVID-19, [키워드] AIDS Autoimmune Bacterial infection calcineurin inhibitors caused coronavirus Coronavirus infections Course COVID-19 cyclophilin cyclosporine Dermatology disease focus Hepatitis hepatitis C hepatitis flu Human human herpesvirus Human immunodeficiency virus human papilloma virus infection immunosuppressive Immunosuppressive treatment include infections Influenza virus inhibitory effect knowledge organ Patient patients treated potential risk property receiving Replication rheumatology risk risk of infections shown tacrolimus the disease Treatment viral infections viruses [DOI] 10.3390/biology9080192 PMC 바로가기 [Article Type] Review
Unexpected SARS-CoV-2 cardiorespiratory arrest in a myopathy patient undergoing immunosuppressive treatment A case report6900 Published on 2020-07-242022-10-30 Journal: Medicine [Category] COVID-19, SARS, [키워드] 2019 novel coronavirus active infection acute exacerbation Asymptomatic cardio-respiratory arrest Cardiopulmonary cardiorespiratory arrest Case report clinical history Coronavirus (COVID-19) diagnosed disease Dysphagia elevated hepatitis C high risk hypoxemic immunosuppressive immunosuppressive therapies immunosuppressive therapy Immunosuppressive treatment Inflammatory inflammatory myopathy Intravenous immunoglobulin Patient patients plasma polymerase chain reaction positive receiving rheumatic disease SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA screened suffered tested the patient therapy unique weakness [DOI] 10.1097/MD.0000000000021377 PMC 바로가기 [Article Type] 6900
Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?Opinion Published on 2020-07-152022-10-28 Journal: BMC Medicine [Category] COVID-19, SARS, [키워드] “cytokine storm” acute respiratory distress acute respiratory syndrome ARDS caused characterized Clinical characteristics clinical symptom conditions coronavirus Coronavirus disease 2019 cough Course COVID-19 cytokine release death disease Diseases Dyspnea fatigue Fever hemophagocytic lymphohistiocytosis HLH hyperinflammation Hyperinflammatory syndrome identify immunosuppressive IMPROVE Infection infections Inflammatory Inflammatory response Laboratory test life-threatening majority malignancies mild symptoms multi-organ failure myalgia outcomes Pathogenesis pathogenesis of SARS-CoV-2 Patient patients with COVID-19 Pneumonia rheumatological SARS-CoV-2 screened Severe case severe COVID-19 syndrome therapy triggered [DOI] 10.1186/s12916-020-01682-y PMC 바로가기 [Article Type] Opinion
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatologyCommentary Published on 2020-07-092022-10-31 Journal: Immunotherapy [Category] COVID-19, MERS, SARS, [키워드] Affect Antimalarials coronavirus COVID-19 Dermatology IL12/13 IL17 IL23 IL6 inhibitor immune-mediated diseases immunosuppressive JAK inhibitor Patient receiving rheumatology SARS-CoV-2 [DOI] 10.2217/imt-2020-0153 PMC 바로가기 [Article Type] Commentary
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trialLetter Published on 2020-07-092022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 absence Admission allergy alteration Antibody test anticipated Antigen approved assigned blinded breast-feeding Burgos Cancer chronic liver disease cirrhosis clearance clinical clinical symptom clinical trial Complete Corticosteroid Course COVID-19 COVID19 creatinine criteria delirium Department Desaturation Deterioration diabete Diagnosis dissemination drug Dyspnea Early pulmonary early stage Effectiveness element Emergency EudraCT evaluate exclusion for inclusion glucocorticoid greater group heart hidden history HIV infection hospital Hospital admission Hospital stay Hydroxychloroquine hypertension ICU admission Immunosuppression immunosuppressive include Inclusion intention-to-treat basis interactions Intervention local Ethics Committee lung lung involvement meet mild pneumonia modify number objective observation Occurrence Other other diseases outcome Outpatient outpatients Paracetamol parallel group participant Participation Patient patients’ medical records PCR per protocol performed physician Pneumonia power of 80% Prednisone professionals protocol pulmonary involvement QT prolongation radiological random randomised randomised controlled trial Randomized receive recruitment reduce reflected Registered renal responsible risk Sample size SARS-COV-2 infection sealed secondary sequence Spain Spanish status steroid Steroids stratified Stratified randomization study drug study inclusion subject Symptom the patient Treatment Trial verbal website women X-ray [DOI] 10.1186/s13063-020-04575-w PMC 바로가기 [Article Type] Letter
Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic reviewReview Article Published on 2020-07-072024-09-04 Journal: Dermatologic therapy [Category] 대상포진, [키워드] biologic Concomitant concurrent Corona virus COVID‐19 Cutaneous immunobullous immunomodulator immunosuppressive manifestation novel human coronavirus (SARS‐CoV‐2) pemphigoid pemphigus psoriasis psoriatic arthritis Simultaneous skin specific skin disease systematic review systemic drug [DOI] 10.1111/dth.13867 PMC 바로가기 [Article Type] Review Article
Analysis of ACE2 Gene-Encoded Proteins Across Mammalian SpeciesVeterinary Science Published on 2020-07-032022-11-01 Journal: Frontiers in Veterinary Science [Category] COVID-19, [키워드] ACE2 ACE2 gene acute respiratory syndrome Analysis analyzed angiotensin-converting enzyme 2 binding caused chronic disease close contact coded coronavirus coronavirus disease correlation COVID-19 Data analysis Felis homologous homology host cell Human human ACE2 receptor humans immunosuppressive Infection infection process mammalian mammals novel Novel coronavirus Pneumonia predicted Predictive Protein public health Rattus receptor required SARS-CoV-2 Specy spike-protein suggested susceptibility susceptible Transmission virus [DOI] 10.3389/fvets.2020.00457 PMC 바로가기 [Article Type] Veterinary Science
Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, ChinaCase Report Published on 2020-07-022022-10-29 Journal: Infectious Diseases of Poverty [Category] COVID-19, SARS, [키워드] acute respiratory syndrome advanced age B cell B cells Bacteria Cancer cancer patient Cancer patients CD3 Characteristics Chemotherapy clinical clinical feature combination therapy contribute coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-2019 dead decrease diagnosed fungi hepatitis B Hepatocellular carcinoma hospital immune system immunosuppressive Infection leukemia Liver transplantation lymphocyte Mild natural killer cell outbreak Patient Pneumonia Radiotherapy Respiratory Support SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome coronavirus 2 severity of COVID-19 suffered survived susceptible T cells therapy Treatment tumors underlying disease underlying diseases viral infection virus were infected Wuhan Wuhan, China [DOI] 10.1186/s40249-020-00707-1 PMC 바로가기 [Article Type] Case Report